Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium difficile | 11 | 2016 | 22 | 2.960 |
Why?
|
| Clostridium Infections | 7 | 2019 | 13 | 2.300 |
Why?
|
| Enterocolitis, Pseudomembranous | 6 | 2015 | 13 | 1.820 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2026 | 40 | 1.520 |
Why?
|
| Cross Infection | 7 | 2019 | 22 | 1.510 |
Why?
|
| Vaccination | 9 | 2026 | 725 | 1.350 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2026 | 158 | 1.220 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2026 | 29 | 1.150 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2026 | 12 | 1.100 |
Why?
|
| Young Adult | 20 | 2026 | 2456 | 0.980 |
Why?
|
| Humans | 52 | 2026 | 16832 | 0.970 |
Why?
|
| Adult | 31 | 2026 | 7255 | 0.940 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 24 | 0.860 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 352 | 0.830 |
Why?
|
| Male | 33 | 2026 | 9556 | 0.790 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 239 | 0.780 |
Why?
|
| Female | 35 | 2026 | 12193 | 0.760 |
Why?
|
| Health Personnel | 5 | 2022 | 132 | 0.750 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 353 | 0.710 |
Why?
|
| Accelerometry | 1 | 2021 | 48 | 0.650 |
Why?
|
| Middle Aged | 25 | 2026 | 7515 | 0.640 |
Why?
|
| Incidence | 11 | 2026 | 1229 | 0.640 |
Why?
|
| Adolescent | 22 | 2026 | 3464 | 0.640 |
Why?
|
| Pericarditis | 2 | 2018 | 11 | 0.580 |
Why?
|
| Infant | 10 | 2026 | 1212 | 0.560 |
Why?
|
| Health Services | 2 | 2016 | 100 | 0.550 |
Why?
|
| Myocarditis | 2 | 2018 | 14 | 0.550 |
Why?
|
| Population Surveillance | 3 | 2014 | 242 | 0.550 |
Why?
|
| Aged | 18 | 2026 | 5901 | 0.540 |
Why?
|
| Viral Vaccines | 1 | 2018 | 12 | 0.540 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 10 | 0.540 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 44 | 0.540 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 14 | 0.530 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 174 | 0.530 |
Why?
|
| Oregon | 7 | 2026 | 168 | 0.530 |
Why?
|
| Family Characteristics | 3 | 2026 | 69 | 0.530 |
Why?
|
| Deprescriptions | 1 | 2018 | 12 | 0.530 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 35 | 0.520 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 186 | 0.510 |
Why?
|
| Ambulatory Care | 2 | 2015 | 205 | 0.480 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 185 | 0.480 |
Why?
|
| Exercise | 1 | 2021 | 513 | 0.470 |
Why?
|
| Public Health Surveillance | 2 | 2022 | 42 | 0.470 |
Why?
|
| Washington | 6 | 2026 | 376 | 0.470 |
Why?
|
| Risk Management | 1 | 2016 | 3 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.460 |
Why?
|
| Paramyxoviridae Infections | 2 | 2026 | 8 | 0.460 |
Why?
|
| Medication Adherence | 2 | 2017 | 235 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 262 | 0.450 |
Why?
|
| Risk | 2 | 2022 | 453 | 0.430 |
Why?
|
| Retrospective Studies | 10 | 2026 | 2463 | 0.420 |
Why?
|
| Decision Making | 2 | 2017 | 164 | 0.410 |
Why?
|
| Viral Load | 3 | 2026 | 141 | 0.390 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 1204 | 0.380 |
Why?
|
| Influenza, Human | 3 | 2026 | 292 | 0.380 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 19 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2026 | 1186 | 0.370 |
Why?
|
| Child | 12 | 2026 | 2433 | 0.370 |
Why?
|
| Risk Factors | 9 | 2026 | 3108 | 0.360 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 60 | 0.360 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 197 | 0.360 |
Why?
|
| Child, Preschool | 8 | 2026 | 1430 | 0.360 |
Why?
|
| Health Expenditures | 1 | 2012 | 69 | 0.350 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 374 | 0.340 |
Why?
|
| Northwestern United States | 4 | 2021 | 53 | 0.330 |
Why?
|
| Antibodies, Viral | 3 | 2026 | 70 | 0.330 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 1887 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 4 | 2016 | 145 | 0.290 |
Why?
|
| United States | 11 | 2026 | 3858 | 0.280 |
Why?
|
| Metapneumovirus | 2 | 2026 | 7 | 0.280 |
Why?
|
| Colorado | 3 | 2014 | 171 | 0.280 |
Why?
|
| Personnel, Hospital | 1 | 2008 | 7 | 0.270 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 13 | 0.270 |
Why?
|
| Hospitals, Rural | 1 | 2007 | 6 | 0.270 |
Why?
|
| Pregnancy | 4 | 2026 | 1555 | 0.260 |
Why?
|
| Cohort Studies | 6 | 2026 | 2396 | 0.260 |
Why?
|
| Hospitalization | 5 | 2022 | 816 | 0.250 |
Why?
|
| Qualitative Research | 2 | 2018 | 288 | 0.240 |
Why?
|
| Enterovirus Infections | 1 | 2026 | 3 | 0.240 |
Why?
|
| Enterovirus D, Human | 1 | 2026 | 3 | 0.240 |
Why?
|
| Genome, Viral | 1 | 2026 | 8 | 0.240 |
Why?
|
| Respiratory Tract Infections | 1 | 2026 | 58 | 0.230 |
Why?
|
| Genetic Variation | 1 | 2026 | 67 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2026 | 99 | 0.230 |
Why?
|
| Intention | 1 | 2025 | 28 | 0.220 |
Why?
|
| Parents | 2 | 2025 | 298 | 0.210 |
Why?
|
| Emergency Responders | 2 | 2021 | 4 | 0.210 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 300 | 0.210 |
Why?
|
| Case-Control Studies | 5 | 2019 | 995 | 0.200 |
Why?
|
| Pharmacists | 2 | 2021 | 53 | 0.200 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 657 | 0.190 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2014 | 199 | 0.180 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 46 | 0.180 |
Why?
|
| Vancomycin | 2 | 2012 | 4 | 0.180 |
Why?
|
| Child Abuse, Sexual | 1 | 2021 | 13 | 0.180 |
Why?
|
| Angioedema | 1 | 2021 | 5 | 0.170 |
Why?
|
| Occupations | 1 | 2021 | 15 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.170 |
Why?
|
| Vital Signs | 1 | 2021 | 12 | 0.170 |
Why?
|
| Occupational Diseases | 1 | 2021 | 33 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2026 | 13 | 0.160 |
Why?
|
| Time Factors | 4 | 2022 | 989 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 215 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2012 | 569 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 161 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 114 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2019 | 382 | 0.150 |
Why?
|
| Logistic Models | 3 | 2015 | 796 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 120 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 183 | 0.150 |
Why?
|
| Veterans Health | 1 | 2019 | 16 | 0.150 |
Why?
|
| Railroads | 1 | 2019 | 3 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 113 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 346 | 0.140 |
Why?
|
| Syncope | 1 | 2018 | 11 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 226 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 10 | 0.140 |
Why?
|
| Acute Pain | 1 | 2018 | 10 | 0.140 |
Why?
|
| Environment Design | 1 | 2019 | 65 | 0.140 |
Why?
|
| Length of Stay | 2 | 2010 | 169 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 17 | 0.140 |
Why?
|
| Life Change Events | 1 | 2018 | 26 | 0.130 |
Why?
|
| Infection Control | 2 | 2007 | 8 | 0.130 |
Why?
|
| Adolescent Health Services | 1 | 2018 | 36 | 0.130 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 4 | 0.120 |
Why?
|
| Child Health Services | 1 | 2018 | 104 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 186 | 0.120 |
Why?
|
| Electronic Health Records | 3 | 2019 | 702 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2022 | 1047 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 149 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2018 | 132 | 0.120 |
Why?
|
| Heart Failure | 1 | 2021 | 403 | 0.120 |
Why?
|
| Trimethoprim | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 13 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 15 | 0.120 |
Why?
|
| Patient Admission | 1 | 2016 | 58 | 0.110 |
Why?
|
| Forecasting | 1 | 2016 | 67 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 169 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 45 | 0.110 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 3 | 0.110 |
Why?
|
| Vaccines | 1 | 2018 | 225 | 0.110 |
Why?
|
| Algorithms | 1 | 2016 | 210 | 0.110 |
Why?
|
| Self Administration | 1 | 2014 | 7 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2016 | 164 | 0.110 |
Why?
|
| Electronic Mail | 1 | 2014 | 52 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 477 | 0.100 |
Why?
|
| Inpatients | 1 | 2014 | 78 | 0.100 |
Why?
|
| Outpatients | 1 | 2014 | 99 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2015 | 294 | 0.100 |
Why?
|
| Telephone | 1 | 2014 | 157 | 0.100 |
Why?
|
| Prognosis | 1 | 2014 | 568 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 206 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 516 | 0.090 |
Why?
|
| Metronidazole | 1 | 2012 | 3 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 207 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 39 | 0.090 |
Why?
|
| Iowa | 2 | 2007 | 38 | 0.080 |
Why?
|
| Seasons | 2 | 2026 | 114 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 137 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 2010 | 16 | 0.080 |
Why?
|
| California | 1 | 2016 | 2244 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2026 | 828 | 0.070 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 14 | 0.070 |
Why?
|
| Administrative Personnel | 1 | 2008 | 5 | 0.070 |
Why?
|
| Infection Control Practitioners | 1 | 2007 | 1 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 36 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2008 | 65 | 0.070 |
Why?
|
| Borrelia burgdorferi Group | 2 | 1998 | 2 | 0.060 |
Why?
|
| Lyme Disease | 2 | 1998 | 4 | 0.060 |
Why?
|
| DNA, Bacterial | 2 | 1998 | 10 | 0.060 |
Why?
|
| Phylogeny | 1 | 2026 | 18 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 108 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 33 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2026 | 160 | 0.050 |
Why?
|
| Premature Birth | 1 | 2026 | 133 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2021 | 693 | 0.050 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 1 | 0.050 |
Why?
|
| Yersinia Infections | 1 | 1982 | 1 | 0.050 |
Why?
|
| Arthritis, Reactive | 1 | 1982 | 1 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 3 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 6 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 11 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 66 | 0.050 |
Why?
|
| Thrombosis | 1 | 2022 | 16 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2022 | 32 | 0.050 |
Why?
|
| Alberta | 1 | 2021 | 4 | 0.040 |
Why?
|
| Internet | 1 | 2023 | 207 | 0.040 |
Why?
|
| Carrier State | 1 | 2021 | 7 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2021 | 9 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 237 | 0.040 |
Why?
|
| Sacrococcygeal Region | 1 | 2001 | 1 | 0.040 |
Why?
|
| Diskectomy | 1 | 2001 | 1 | 0.040 |
Why?
|
| Prednisolone | 1 | 2001 | 4 | 0.040 |
Why?
|
| Sciatica | 1 | 2001 | 2 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2001 | 3 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1098 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2001 | 16 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 80 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 112 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 1998 | 4 | 0.030 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2018 | 4 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1233 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 38 | 0.030 |
Why?
|
| Nails, Malformed | 1 | 1997 | 1 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 34 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 56 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1997 | 17 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 210 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 261 | 0.030 |
Why?
|
| Child Abuse | 1 | 2018 | 44 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 244 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 29 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2017 | 85 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1996 | 1 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 15 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 84 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 290 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 785 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 475 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 23 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 81 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 88 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 187 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 112 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 7 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 35 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 48 | 0.020 |
Why?
|
| Hospitals | 1 | 2007 | 69 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 223 | 0.020 |
Why?
|
| Endocarditis | 1 | 1982 | 1 | 0.010 |
Why?
|
| Yersinia enterocolitica | 1 | 1982 | 1 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1982 | 23 | 0.010 |
Why?
|
| Epidural Space | 1 | 2001 | 2 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2001 | 6 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 6 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 138 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 32 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1996 | 1 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 14 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 16 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1996 | 23 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 291 | 0.010 |
Why?
|
Concepts
(249)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->